论文部分内容阅读
目的观察周剂量多西他赛联合卡培他滨治疗晚期胃癌的近期疗效和不良反应。方法 37例晚期胃癌患者采用多西他赛35mg/m2,静脉滴注,第1,8天;卡培他滨1250mg/m2,bid,口服,1～14d,21d为1周期。3周期后评价疗效和不良反应。结果全组37例患者均可评价疗效,其中CR3例(8.1%),PR19例(51.3%),SD10例(27.0%),PD5例(13.5%),总有效率59.5%。中性粒细胞减少发生率54.0%。中位TTP为6.5个月(3.2～11.5个月),中位MST为10.3个月(5.8～14.7个月)。结论多西他赛联合卡培他滨治疗晚期胃癌有效率较高,血液学毒性低,近期疗效较好,用药方便、安全,明显提高了患者的生活质量。
Objective To observe the short-term curative effect and adverse reactions of weekly dose docetaxel plus capecitabine in the treatment of advanced gastric cancer. Methods 37 patients with advanced gastric cancer were treated with docetaxel 35mg / m2 intravenously, on the first and eighth days; capecitabine 1250mg / m2, bid, orally, 1 ~ 14d and 21d for one cycle. Three cycles after the evaluation of efficacy and adverse reactions. Results There were 37 patients (8.1%) in CR, 51 (51.3%) in PR, 10 (27.0%) in SD, and 13.5% (5) in PD. The total effective rate was 59.5%. The incidence of neutropenia was 54.0%. The median TTP was 6.5 months (3.2 to 11.5 months) and the median MST was 10.3 months (5.8 to 14.7 months). Conclusion Docetaxel combined with capecitabine is effective in treating advanced gastric cancer, with low hematological toxicity and better curative effect in the short term. It is convenient and safe to use, and significantly improves the quality of life of patients.